Scherpereel
A
et al; French Cooperative Thoracic Intergroup.
Nivolumab or
nivolumab plus
ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019 Feb;20(2):239–53.
[PubMed: 30660609]